Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7058276 | 0.98 | SMN1; SMN2 (0.31) | SMN1; SMN2MMP12 | |
| SCHEMBL27639275 | 0.92 | MAPT (0.42) | SMN1; SMN2MMP12ALDH1A1HPGDKDM4E | |
| SCHEMBL549125 | 0.78 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1HPGDMAPTRAB9A | |
| Hydrochloric Acid SCHEMBL7055126 | 0.77 | ALDH1A1 (0.32) | SMN1; SMN2ALDH1A1HPGDMAPTRAB9A | |
| SCHEMBL549244 | 0.76 | ROCK2 (0.40) | SMN1; SMN2MMP12ALDH1A1HPGDKDM4E | |
| SCHEMBL25654653 | 0.73 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1HPGDGAAMAPT | |
| SCHEMBL6363206 | 0.72 | MEN1 (0.44) | SMN1; SMN2ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL549279 | 0.72 | PRMT7 (0.40) | MMP12ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL5143734 | 0.71 | LNPEP (0.36) | SMN1; SMN2ALDH1A1HPGDKDM4EGLA | |
| Hydrochloric Acid SCHEMBL6362908 | 0.71 | MEN1 (0.43) | SMN1; SMN2ALDH1A1HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | FINSINGER DIRK (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8110583-B2 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004002430-A2 | COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | COMBINATORX INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | TP53, IDH3A, IDH2 | SMN1; SMN2 2473/4885MMP12 3775/4885ALDH1A1 347/4885 |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | SMN1; SMN2 2362/4885MMP12 2299/4885ALDH1A1 571/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | SMN1; SMN2 1821/4885MMP12 859/4885ALDH1A1 662/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | SMN1; SMN2 611/4885MMP12 921/4885ALDH1A1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.